Capital One Financial analyst Tim Chiang maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report) today and set a price target of $55.00.
Tim Chiang has given his Buy rating due to a combination of factors surrounding Jasper Therapeutics’ promising developments and anticipated milestones. Jasper Therapeutics is in the process of advancing their lead product candidate, briquilimab, which targets a significant patient population suffering from chronic spontaneous urticaria (CSU). Chiang notes that a large number of these patients are not responding well to current treatments, indicating a substantial market opportunity for briquilimab. Furthermore, Chiang points out that upcoming clinical data readouts, especially from the BEACON CSU study, are expected to significantly influence Jasper Therapeutics’ stock performance in 2024.
Moreover, Chiang’s analysis suggests that the increased serum levels achieved through subcutaneous administration of briquilimab may allow for less frequent dosing intervals, potentially every 2-3 months, which could enhance patient compliance and marketability. He also emphasizes the potential for major success if the Phase 1b/2a BEACON CSU study demonstrates briquilimab’s efficacy at certain doses with minimal side effects. The initiation of the SPOTLIGHT CIndU study and the involvement of a renowned investigator in the field further support the optimistic outlook. These factors collectively contribute to the Buy rating, as they represent significant advancements in Jasper Therapeutics’ pipeline and the possibility of addressing unmet medical needs in the CSU patient population.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Jasper Therapeutics (JSPR) Company Description:
Amplitude Healthcare Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Read More on JSPR:
- Fly Insider: Jasper, AMD among week’s notable insider trades
- Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
- Jasper Therapeutics Announces Offering Pricing Details
- Jasper Therapeutics Launches $50M Share Offering
- Jasper prices 3.9M shares at $12.95 per share in underwritten offering
